The stock trades below cash value, which may attract value-oriented investors, but the company remains pre-revenue on its core ViraxImmune platform. Monitor for revenue generation from the ImmuneSelect Fosun agreement and clinical/regulatory milestones for ViraxImmune. The improved balance sheet and Nasdaq compliance reduce near-term distress risk, but execution on commercial and clinical fronts is critical.
Price Chart
Executive Summary
Virax Biolabs CEO James Foster provided a shareholder update summarizing fiscal 2026 audited results (cash $6.4M, total assets $8.3M, net loss improved to $5.0M from $6.1M), a subsequent $3.3M preferred investment option exercise, a commercial supply agreement with Fosun Diagnostics for ImmuneSelect across six Southeast Asian markets, and Nasdaq compliance regained after a 1-for-25 reverse split. The company's public market valuation ($3M market cap) remains below its audited cash balance, which management highlights as a disconnect.
Key Facts
- Cash of $6.4 million as of March 31, 2026
- Total assets $8.3 million, total liabilities $1.0 million
- Net loss decreased to $5.0 million in fiscal 2026 from $6.1 million in fiscal 2025
- Subsequent financing: preferred investment option exercise for gross proceeds of approximately $3.3 million
- Multi-country commercial supply agreement with Fosun Diagnostics for ImmuneSelect in six Southeast Asian markets
- Nasdaq confirmed compliance with minimum bid price requirement after 1-for-25 share consolidation
- R&D expenses increased to $3.7 million from $2.0 million; G&A expenses decreased to $2.7 million from $4.0 million
Financial Impact
Company holds $6.4M cash against a ~$3M market cap; net loss improved by $1.1M YoY; $3.3M additional gross proceeds from option exercise strengthen liquidity
Risk Factors
- No approved products or recurring revenue; ImmuneSelect is research-use-only
- ViraxImmune is in development and not approved for diagnostic use in any jurisdiction
- Micro-cap volatility and low liquidity; historical stock moves have been extreme
- Forward-looking statements about valuation disconnect may not materialize
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-305400 |
| Document: vrax-ex99_1.htm | 0001193125-26-305400 |
| Document: 0001193125-26-305400-index-headers.html | 0001193125-26-305400 |
| Document: 0001193125-26-305400-index.html | 0001193125-26-305400 |
| Document: 0001193125-26-305400.txt | 0001193125-26-305400 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 6-K | $1.85 | awaiting T+60 | — | $1.19 (−35.68%) |
Sep 4, 2026 7w ago | 6-K | $2.63 | awaiting T+60 | — | $1.19 (+54.75%) |
Sep 4, 2026 7w ago | EFFECT | $2.63 | awaiting T+60 | — | $1.19 (−54.67%) |
Aug 18, 2026 9w ago | 6-K | $2.76 | awaiting T+60 | — | $1.19 (−56.88%) |
Jul 31, 2026 12w ago | 6-K | $2.62 $1.19 | ▲ +54.58% | ▲ +57.04% | $1.19 (+54.58%) |
Jul 16, 2026 14w ago | 6-K | $3.90 $1.87 | ▼ −52.05% | ▼ −55.76% | $1.19 (−69.49%) |
Jul 9, 2026 15w ago | Press Release | $6.36 $2.20 | ▲ +65.41% | ▲ +67.04% | $1.19 (+81.29%) |
Jul 9, 2026 15w ago | 6-K | $6.36 $2.20 | ▼ −65.41% | ▼ −67.04% | $1.19 (−81.29%) |
Jun 24, 2026 17w ago | 6-K | $0.1350 $0.0924 | ▼ −31.56% | ▼ −36.89% | $1.19 (+781.48%) |
Jun 12, 2026 19w ago | 6-K | $0.1840 $0.1092 | ▼ −40.65% | ▼ −43.44% | $1.19 (+546.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers